Citations

Clear

16281 citation(s) found for "Yu, David".

How to Make Meaningful Diagnoses with Abdominal Radiographs: Clues from Natural “Contrast Agents”
DiSantis, David J. , Baumgarten, Deborah A. , Dyer, Raymond B. , Cernigliaro, Joseph G.

Mayo Clinic

RadioGraphics | August 22, 2024 | Volume: 44 | Issue: 9 | Pages: No page available

10.1148/rg.230207 | PMID 39172706 Get It

Substrate Characterization and Outcomes of Ventricular Tachycardia Ablation in Amyloid Cardiomyopathy: A Multicenter Study
Compagnucci, Paolo , Russo, Antonio Dello, Gasperetti, Alessio , Schiavone, Marco , Sehrawat, Ojasav , Hasegawa, Kanae , Liang, Jackson J. , Fazia, Vincenzo Mirco La , Bogun, Frank , Stevenson, William G. , Siontis, Konstantinos C. , Tandri, Harikrishna , Natale, Andrea , Mohanty, Sanghamitra , Liang, Jackson , Kapa, Suraj , La Fazia, Vincenzo Mirco , Stevenson, William , Tondo, Claudio , Siontis, Konstantinos C , Santangeli, Pasquale , Natale, Andrea , Casella, Michela , Compagnucci, Paolo , Russo, Antonio Dello, Kapa, Suraj , Tondo, Claudio , Santangeli, Pasquale

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | August 22, 2024 | Volume: 17 | Issue: 9 | Pages: No page available

10.1161/circep.124.012788 | PMID 39171384 Get It

BACKGROUND: Sustained ventricular tachycardia (VT) in cardiac amyloidosis is uncommon, and the substrate and outcomes of catheter ablation are not defined. METHODS: We included 22 consecutive patients (mean age, 68±10 years; male sex, 91%) with cardiac amyloidosis (ATTR [transthyretin], n=16; light chain, n=6) undergoing catheter ablation for VT/ventricular fibrillation (VF) between 2013 and 2023 in a retrospective, observational, international study. The primary efficacy outcome was recurrent VT/VF during follow-up, while the primary safety end point included major procedure-related adverse events. RESULTS: The indication for ablation was drug-refractory VT in 17 patients (77%), and premature ventricular complex–initiated polymorphic VT/VF in 5 patients (23%). Catheter ablation was performed using endocardial (n=17.77%) or endo-epicardial approaches (n=5.23%). Complete endocardial electroanatomical voltage maps of the left and right ventricles were obtained in 17 (77%) and 10 (45%) patients, respectively. Each patient had evidence of low-voltage areas, most commonly involving the interventricular septum (n=16); late potentials were recorded in 16 patients (73%). A median of 1 (1–2) VT was inducible per patient; 12 of the 26 mappable VTs (46%) originated from the interventricular septum. Complete procedural success was achieved in 16 patients (73%), with 4 (18%) major procedure-related adverse events. After a median follow-up of 32 (14–42) months, sustained VT/VF recurrence was observed in 9 patients (41%); survival free from VT/VF recurrence was 56% (95% CI, 36%–86%) at 36-month follow-up, and most patients remained on antiarrhythmic drugs. A significant reduction in per patient implantable cardioverter defibrillator therapies was noted in the 6-month period after ablation (before: 6 [4–9] versus after: 0 [0–0]; P <0.001). In multivariable analysis, complete procedural success was associated with reduced risk of recurrent VT/VF (hazard ratio, 0.002; P =0.034). CONCLUSIONS: Catheter ablation can achieve control of recurrent VT/VF in more than half of patients with cardiac amyloidosis, and the reduction in VT/VF burden post-ablation may be relevant for quality of life. Septal substrate and risk of procedure-related complications challenge successful management of patients with cardiac amyloidosis and VT/VF.
Insights into mitochondrial creatine kinase: examining preventive role of creatine supplement in doxorubicin-induced cardiotoxicity
Sharif, Salaheddin M. , Hydock, David S.

Mayo Clinic

Toxicology Mechanisms and Methods | August 22, 2024 | Volume: 35 | Issue: 2 | Pages: 136-145

10.1080/15376516.2024.2393825 | PMID 39169611 Get It

Health-related quality of life with gilteritinib vs placebo posttransplant for FLT3-ITD + acute myeloid leukemia
Hamilton, Betty K. , Pandya, Bhavik J. , Ivanescu, Cristina, Elsouda, Dina, Hamadani, Mehdi , Chen, Yi‐Bin , Levis, Mark J. , Ueda, Masumi , Litzow, Mark R. , Soiffer, Robert J. , Üstün, Celalettin , Perl, Alexander E. , Singh, Anurag K. , Geller, Nancy L. , Hasabou, Nahla, Rosales, Matt, Cella, David , Corredoira, Laura, Pestana, Carolina , Horowitz, Mary M. , Logan, Brent R., Ueda Oshima, Masumi , Geller, Nancy , Hamadani, Mehdi

Mayo Clinic

Blood Advances | August 22, 2024 | Volume: 8 | Issue: 19 | Pages: 5091-5099

10.1182/bloodadvances.2024013746 | PMID 39167766 Get It

Abstract The Blood and Marrow Transplant (BMT) Clinical Trials Network conducted a phase 3 randomized trial comparing gilteritinib with placebo after allogeneic hematopoietic cell transplantation (HCT) for FLT3-ITD+ acute myeloid leukemia (AML). The primary analysis demonstrated no statistically significant difference in relapse-free survival (RFS); however, patients with FLT3-ITD measurable residual disease (MRD) peri-HCT had significantly longer RFS with gilteritinib. This analysis investigates the effect of post-HCT gilteritinib vs placebo on health-related quality of life (HRQOL). HRQOL was measured with Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), FACT-Leukemia (FACT-Leu), and EuroQOL-5 Dimensions (EQ-5D-5L) at post-HCT randomization; day 29; months 3, 6, 12, 18, 24; and/or end of therapy. HRQOL and clinically meaningful differences were summarized using descriptive statistics and compared using mixed model repeated measures to evaluate longitudinal change from baseline and stratified Cox model to evaluate time to improvement. HRQOL completion rate was acceptable (&gt;70%) across all time points and measures. There were no differences in HRQOL scores at any time point between cohorts. Clinically meaningful and time to improvement in HRQOL were similar in both arms. Despite higher treatment-emergent adverse effects with gilteritinib, response to the question of being “bothered by side effects of treatment” did not differ between groups. Subgroup analysis of MRD-positive and negative patients demonstrated no differences in HRQOL between arms. For patients with FLT3-ITD+ AML undergoing HCT, gilteritinib maintenance was not associated with any difference in HRQOL or patient-reported impact of side effects. This trial was registered at www.ClinicalTrials.gov as #NCT02997202.
Anatomical evaluation of the superficial parasternal intercostal plane block
Harbell, Monica W. , Nelson, James A. , Seamans, David P. , Craner, Ryan C., Harbell, Monica W , Craner, Ryan, Nelson, James A, Langley, Natalie R.

Mayo Clinic

Regional Anesthesia & Pain Medicine | August 22, 2024 | Volume: 50 | Issue: 12 | Pages: 948-952

10.1136/rapm-2024-105818 | PMID 39174050 Get It

Background and objectives Few cadaveric studies have evaluated the dye spread with superficial parasternal intercostal plane (SPIP) blocks. In this study, we examined the dye spread of an ultrasound-guided SPIP block in a human cadaveric model with single and double injection techniques. Methods Seven single and four double ultrasound-guided SPIP blocks were performed in seven unembalmed human cadavers using an in-plane approach with the transducer oriented parasagitally 1 cm lateral to the sternum. For the single SPIP, 20 mL of 0.166% methylene blue was injected in the second or third intercostal space into the plane between the Pec major muscle and internal intercostal muscles. For the double SPIP, 10 mL of 0.166% methylene blue was injected in the SPIP at one intercostal space with an additional 10 mL injected in the SPIP two intercostal spaces caudally. The extent of dye spread was documented. Results For all SPIP injections, there was consistent mediolateral spread from the sternum to the mid-clavicular line, with many extending laterally to the anterior axillary line. There was craniocaudal spread to a median of 2 intercostal muscles with a single SPIP and 3 intercostal muscles with a double SPIP. There was a median spread to 1 intercostal nerve for the single SPIP and 1.5 intercostal nerves with the double SPIP. Conclusions The SPIP block demonstrated limited spread in this cadaver study. A single injection of this block may be of limited value and multiple SPIP injections may be needed to have adequate spread for anterior thoracic procedures.
Succinate dehydrogenase–complex II regulates skeletal muscle cellular respiration and contractility but not muscle mass in genetically induced pulmonary emphysema
Balnis, Joseph , Tufts, Ankita , Jackson, Emily , Drake, Lisa A. , Singer, Diane V. , Lacomis, David , Lee, Chun Geun , Elias, Jack A. , Doles, Jason D. , Maher, L. James, Coon, Joshua J. , Singer, Harold A. , Vincent, Catherine E., Jaitovich, Ariel, Jen, Annie , Coon, Joshua J , Jourd'heuil, David , Jaitovich, Ariel , Lacomis, David , Doles, Jason D , Drake, Lisa A.

Mayo Clinic

Science Advances | August 21, 2024 | Volume: 10 | Issue: 34 | Pages: No page available

10.1126/sciadv.ado8549 | PMID 39167644 Get It

Reduced skeletal muscle mass and oxidative capacity coexist in patients with pulmonary emphysema and are independently associated with higher mortality. If reduced cellular respiration contributes to muscle atrophy in that setting remains unknown. Using a mouse with genetically induced pulmonary emphysema that recapitulates muscle dysfunction, we found that reduced activity of succinate dehydrogenase (SDH) is a hallmark of its myopathic changes. We generated an inducible, muscle-specific SDH knockout mouse that demonstrates lower mitochondrial oxygen consumption, myofiber contractility, and exercise endurance. Respirometry analyses show that in vitro complex I respiration is unaffected by loss of SDH subunit C in muscle mitochondria, which is consistent with the pulmonary emphysema animal data. SDH knockout initially causes succinate accumulation associated with a down-regulated transcriptome but modest proteome effects. Muscle mass, myofiber type composition, and overall body mass constituents remain unaltered in the transgenic mice. Thus, while SDH regulates myofiber respiration in experimental pulmonary emphysema, it does not control muscle mass or other body constituents.
The Future of Healthcare Delivery: Three Insights from Supply Chain Management
Francis, James R. , Bagchi, Ann D. , Melamed, Benjamin , Hill, Diane, Baveja, Alok , Ding, Xin David

Mayo Clinic

Management and Business Review | August 21, 2024 | Volume: 3 | Issue: 4 | Pages: 28-36

10.1177/2694105820230304007 Get It

The COVID-19 pandemic dramatically exposed the vulnerabilities of supply chains in the healthcare sector. James R. Francis, Alok Baveja, Xin (David) Ding, Ann D. Bagchi, Benjamin Melamed, and Diane Hill conducted an in-depth study of how Mayo Clinic addressed these challenges and present three strategies for the future of the healthcare industry.
Thrombolysis for Ischemic Stroke Despite Recent Ingestion of Direct Oral Anticoagulants – A Growing Dilemma Also in India
Meinel, Thomas R. , Menon, Bijoy K. , Fischer, Urs , Seiffge, David , Paramasivan, Naveen K, Fischer, Urs , Seiffge, David , Paramasivan, Naveen Kumar

Mayo Clinic

Annals of Indian Academy of Neurology | August 20, 2024 | Volume: 27 | Issue: 4 | Pages: 345-351

10.4103/aian.aian_524_24 | PMID 39196805 Get It

The administration of intravenous thrombolysis (IVT) for patients with acute ischemic stroke who have recently ingested direct oral anticoagulants (DOACs) presents a clinical challenge due to the perceived increased risk of intracranial hemorrhage (ICH). Traditional guidelines from the US and European authorities advise against IVT within 48 h of last DOAC ingestion, unless specific coagulation tests indicate safety. However, emerging observational studies suggest that IVT might be safe in selected patients. A US stroke registry study and a global multicenter cohort study both reported no significant increase in symptomatic ICH among patients on DOACs compared to those not on anticoagulants. A systematic review of all published observational studies further supported these findings, showing comparable bleeding rates and functional outcomes in DOAC-treated patients. Reversal agents like idarucizumab for dabigatran have demonstrated potential in facilitating safer IVT administration, though logistical and cost-related barriers limit their widespread use. The variability in global guidelines reflects differing approaches to risk assessment and resource availability, highlighting the need for individualized treatment decisions. In India, the increasing prevalence of atrial fibrillation and stroke as well as prescription of DOACs necessitate adapted guidelines that consider local health-care infrastructure. Despite the promising observational data, the lack of randomized controlled trials underscores the need for further research to establish robust evidence for IVT use in this context. Collaborative international efforts and inclusion of diverse patient populations in future studies will be crucial to refine treatment protocols and improve outcomes for stroke patients on DOACs.
Tranexamic Acid in Patients Undergoing Liver Resection
Karanicolas, Paul J. , Lin, Yulia , McCluskey, Stuart A. , Tarshis, Jordan , Dixon, Elijah , Porter, Geoff , Chaudhury, Prosanto , Nanji, Sulaiman , Ruo, Leyo , Tsang, Melanie E. , Skaro, Anton , Eeson, Gareth, Moulton, Carol-Anne, Ball, Chad G. , Hallet, Julie, Coburn, Natalie, Jayaraman, Shiva, Law, Calvin, Tandan, Ved, Nagorney, David, Quan, Douglas , Smoot, Rory L. , Gallinger, Steven, Metrakos, Peter , Reichman, Trevor , Jalink, Diederick, Bennett, Sean, Sutherland, Francis, Solano, Edward, Molinari, Michele , Tang, Ephraim , Bathe, Oliver F. , Barkun, Jeffrey , Kendrick, Michael L., Truty, Mark J. , Roke, Rachel , Xu, Grace , Lafrenière‐Roula, Myriam , Team, HPB CONCEPT, Truty, Mark, Smoot, Rory L , Thorpe, Kevin E. , Wei, Alice C. , Cleary, Sean P. , Serrano, Pablo E , Sapisochín, Gonzalo , Warner, Susanne G. , Kendrick, Michael L. , Guyatt, Gordon , Team, HPB CONCEPT

Mayo Clinic

JAMA | August 19, 2024 | Volume: 332 | Issue: 13 | Pages: 1080

10.1001/jama.2024.11783 | PMID 39158894 Get It

ImportanceTranexamic acid reduces bleeding and blood transfusion in many types of surgery, but its effect in patients undergoing liver resection for a cancer-related indication remains unclear.ObjectiveTo determine whether tranexamic acid reduces red blood cell transfusion within 7 days of liver resection.Design, Setting, and ParticipantsMulticenter randomized clinical trial of tranexamic acid vs placebo conducted from December 1, 2014, to November 8, 2022, at 10 hepatopancreaticobiliary sites in Canada and 1 site in the United States, with 90-day follow-up. Participants, clinicians, and data collectors were blinded to allocation. A volunteer sample of 1384 patients undergoing liver resection for a cancer-related indication met eligibility criteria and consented to randomization.InterventionsTranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n = 619) or matching placebo (n = 626) beginning at induction of anesthesia.Main Outcomes and MeasuresThe primary outcome was receipt of red blood cell transfusion within 7 days of surgery.ResultsThe primary analysis included 1245 participants (mean age, 63.2 years; 39.8% female; 56.1% with a diagnosis of colorectal liver metastases). Perioperative characteristics were similar between groups. Red blood cell transfusion occurred in 16.3% of participants (n = 101) in the tranexamic acid group and 14.5% (n = 91) in the placebo group (odds ratio, 1.15 [95% CI, 0.84-1.56]; P = .38; absolute difference, 2% [95% CI, −2% to 6%]). Measured intraoperative blood loss (tranexamic acid, 817.3 mL; placebo, 836.7 mL; P = .75) and total estimated blood loss over 7 days (tranexamic acid, 1504.0 mL; placebo, 1551.2 mL; P = .38) were similar between groups. Participants receiving tranexamic acid experienced significantly more complications compared with placebo (odds ratio, 1.28 [95% CI, 1.02-1.60]; P = .03), with no significant difference in venous thromboembolism (odds ratio, 1.68 [95% CI, 0.95-3.07]; P = .08).Conclusions and RelevanceAmong patients undergoing liver resection for a cancer-related indication, tranexamic acid did not reduce bleeding or blood transfusion but increased perioperative complications.Trial RegistrationClinicalTrials.gov Identifier: NCT02261415
THE EFFECT OF CEMENTED FEMORAL COMPONENT DESIGN AND PROPHYLACTIC WIRE PLACEMENT AGAINST EARLY PERIPROSTHETIC FEMORAL FRACTURE IN PRIMARY TOTAL HIP ARTHROPLASTY: A BIOMECHANICAL STUDY
Zhao, Guangyue , Labott, Joshua R. , Restrepo, David J. , Hooke, Alexander W. , Zhao, Chunfeng , Perez, Sergio F. Guarin , Tsukamoto, Ichiro , Sierra, Rafael J.

Mayo Clinic

Orthopaedic Proceedings | August 19, 2024 | Volume: 106-B | Issue: SUPP_16 | Pages: 45-45

10.1302/1358-992x.2024.16.045 Get It

Previous studies have highlighted differences in the risk of periprosthetic fracture between tapered slip (TS) and composite beam (CB) stems. This biomechanical study explored periprosthetic fractures around these stems and the effect of adding a 16-gauge calcar or diaphyseal wire to TS stems on their resistance to torque.A power analysis determined a sample size of 7 specimens per group, assuming a standard deviation of 14.8 Nm in peak torque, to provide 90% power to detect a difference of at least 30 Nm between groups. Twenty-one TS stems (eight alone, six with calcar wiring, seven with diaphyseal wiring placed 2 cm distal to the lesser trochanter) and seven CB stems were cemented into standard Sawbones. A servo-hydraulic test machine applied a 1000 N load with a 1-degree rotation per second until failure. The peak torque at failure was measured, and the fracture location recorded. Comparisons were performed using two-sample t-tests.CB stems exhibited a significantly higher peak torque at failure (205.3 Nm) than TS stems (159.5 Nm, p=0.020). Calcar-wire-TS (148.2 Nm, p=0.036) and diaphyseal-wire-TS (164.9 Nm, p=0.036) were both weaker than CB stems. Wired-TS stems showed no significant difference from non-wired-TS stems. Additionally, the study could not conclude that calcar wiring is stronger than diaphyseal wiring. All TS fractures occurred at the mid-stem, simulating a B-type fracture, while the addition of the diaphyseal wire shifted the fracture location more distally in four of seven stems (p=0.0699).This biomechanical study supports the clinical evidence that CB stems have stronger resistance to torque than TS stems and may explain lower risk of periprosthetic fracture. The addition of calcar or diaphyseal wires to TS stems resulted in no significant changes in peak torque to fracture. In patients at high risk of periprosthetic fracture, CB cemented stems should be considered.